-
Hypertriglyceridemia (HTG) is an important metabolic disease and strongly associated with the development of hypertension, atherosclerosis, coronary artery disease, and type 2 diabetes mellitus (T2DM). HTG risk is affected by various factors and might occur owing to the complex synergistic interaction between the genetic background and environmental factors[1].
Among peroxisome proliferator-activated receptors (PPARs), PPARγ is an isotype that was recognized to play a major role in the regulation of fatty acid metabolism, probably in the adipose tissue storage and free fatty acids reduction. Several studies suggested that the single nucleotide polymorphisms (SNPs) in PPARγ including rs10865710, rs1805192, and rs709158 are associated with HTG related diseases. However, the results obtained from these studies remain controversial.
Angiotensin Ⅱ type Ⅰ receptor (AGTR1) is a G-protein-coupled receptor of angiotensin Ⅱ that is a peptide hormone and plays a fundamental role as a vasoconstrictor in the regulation of cardiovascular function, renal homeostasis, oxidative stress, and lipid and cholesterol metabolism[2]. During the past decades, several studies reported the association between the AGTR1 polymorphisms and risk of HTG-related diseases. HTG risk is affected by several gene polymorphisms or interactions among several genes and PPARγ as well as AGTR1 are risk factors of HTG-associated diseases; however, to date, merely a few studies focused on the effects of PPARγ-AGTR1 interaction on HTG risk. Therefore, in this study, we aimed to investigate the effect of PPARγ and AGTR1 polymorphisms and synergistic interaction between these two genes on the HTG risk.
In this study, we included a total of 1, 591 participants who were selected from a prospective cohort study of '135' in Soochow, China, that was performed during the period from August, 2012 to March, 2013 and designed to investigate the prevention strategy for chronic diseases[3]. In the current study, the age range of subjects was 53.95 ± 9.61 and the protocol was approved by the independent ethics committee of Suzhou Industrial Park (Soochow, China) in accordance with the Declaration of Helsinki (1975). A written informed consent was obtained from each participant.
The body weight, height, and waist circumference (WC) were measured by following the standardized procedures. Blood pressure (BP) was measured thrice in a seated position with 1 min interval between measurements using a mercury sphygmomanometer. Blood samples were collected in the morning after fasting for at least 8 h. All the plasma and serum samples were frozen at -80 ℃ until their use in the laboratory experiments. Plasma glucose was measured using oxidase enzymatic method.
The triglyceride (TG) levels were quantified and HTG was established according to the criteria defined by the National Cholesterol Education Program (NCEP) Adult Treatment Panel Ⅲ (ATP Ⅲ) that is TG ≥ 1.7 mmol/L.
In this study, all the SNPs were selected based on the criteria of minor allele frequency (MAF) ≥ 0.05 and r2 ≥ 0.8 according to the linkage disequilibrium (LD) values obtained using haploview version 4.2 software. The functional SNPs were analyzed by using the websites of selection tool for SNPs and SNPs with predictive biological effects were retuned as tag-SNPs (Supplementary Table S1, available in www.besjournal.com).
Table Supplementary Table S1. Biological Information about Candidate SNPs of PPARG Gene and AGTR1 Gene
Gene tagSNPs HGVS Nomenclature Chromosome Allelesa Region Biological Effect Transcription Factor Binding Site MAFb, c PPARG rs12631819 NC_000003.12: g.12301362G > T 3 G/T 12301362 intron variant cap 0.378/0.402 rs2920502 NC_000003.12: g.12287696G > C 3 G/C 12287696 upstream variant 2KB cap 0.273/0.244 rs3856806 NC_000003.12: g.12434058C > 3 C/T 12434058 intron variant, synonymous codon, utr variant 3 prime - 0.268/0.250 rs13433696 NC_000003.12: g.12316993G > A 3 G/A 12316993 intron variant Skn-1, cap 0.378/0.390 rs1175543 NC_000003.12: g.12424934A > G 3 A/G 12424934 intron variant CdxA 0.450/0.484 rs9817428 NC_000003.12: g.12298768C > A 3 A/C 12298768 intron variant HSF, SRY 0.435/0.402 rs2972164 NC_000003.12: g.12292917T > C 3 C/T 12292917 intron variant CdxA, Abd-B 0.090/0.073 AGTR1 rs2638360 NC_000003.12: g.148710569G > A 3 T/C 148710569 intron variant CdxA, Dfd, Oct-1, Skn-1, cap, STATx, C/EBPa 0.077/0.156 rs1492100 NC_000003.12: g.148719640T > A 3 A/T 148719640 intron variant Hb 0.122/0.098 rs5182 NC_000003.12: g.148741608C > T 3 T/C 148741608 synonymous codon - 0.306/0.433 rs2933249 NC_000003.12: g.148698733G > A 3 C/T 148698733 intron variant HSF 0.128/0.098 rs275646 NC_000003.12: g.148745735T > C 3 C/T 148745735 - - 0.120/0.110 Note. aMajor/minor allele. bMAF in the control. cMAF in CHB. The DNA extraction and genotyping were performed by following the previously described method[3]. (Supplementary Table S2, available in www.besjournal.com)
Table Supplementary Table S2. The Informations about the Primers and Probes of the Candidate SNPs of PPARG Gene and AGTR1 Gene
Gene SNP Primers and Probes PPARG rs12631819 forward sequence AAATGAGGCCAAAACTTGATAGTGT reverse sequence AAGGTTTACAATAATGCCCAGTACAA probes 1 FAM-AAGTTTAAGAAGAGAACCAG-MGB probes 2 HEX-AGTTTAAGAAGAGAACAAGT-MGB rs2920502 forward sequence GCACAGTAGGGCCCACG reverse sequence GGATCCCTCCTCGGAAATG probes 1 FAM-CCACTCTCTGCCC-MGB probes 2 HEX-CCACTGTCTGCCC-MGB rs3856806 forward sequence CGTCTTCTTGATCACCTGCAGTA reverse sequence AAAATGACAGACCTCAGACAGATTGT probes 1 FAM-CTGCACGTGTTCC-MGB probes 2 HEX-CTGCACATGTTCC-MGB rs13433696 forward sequence GAGGGAGAAAAGGGTTTAGATAAAAGA reverse sequence TGCTCCATCCAGTACATCTATAATTGA probes 1 FAM-AACTTGTTTGGTCTCAGTG-MGB probes 2 VIC-ACTTGTTTGGTCTCAATGA-MGB rs1175543 forward sequence ATGTGAAGCCTCTGGCACAAT reverse sequence ATATAGGGCAAAAGGGAAAATTAGC probes 1 FAM-TTCAGCACACAGTAAA-MGB probes 2 VIC-TTCAGCACACAATAA-MGB rs9817428 forward sequence AAAATAAAACGCATCAGTCTCAGTAGAT reverse sequence GCCAAGACAAACTTCAGCTAACAA probes 1 FAM-ATCATCACATCGAGTTT-MGB probes 2 VIC-TATCATCACATCGAGGTT-MGB rs2972164 forward sequence CTGGACTGGCAAGCCACTCT reverse sequence GCATCCTTTTAGTGAAGTCCCTACTT probes 1 FAM-AGTGTGGAGCTATAAA-MGB probes 2 VIC-AGTGTGGAGCTACAAA-MGB AGTR1 rs2638360 forward sequence GCCAATATTTTCTTCCTTACTCATTACC reverse sequence GTTTGGCTCTCCAACTGCTTAAA probes 1 FAM-TTTCTTTAGTTTTCCAGTAAT-MGB probes 2 HEX-TCTTTAGTTTTCCAATAAT-MGB rs1492100 forward sequence CCTGTGCTGTTCTCAGGTTCTG reverse sequence CACATGGAGTTTCCCTCTCATG probes 1 FAM-ATTGGATGGCTTTTT-MGB probes 2 VIC-ATTGGATGGCTATTTAG-MGB rs5182 forward sequence TGCTTTCCATTATGAGTCCCAAA reverse sequence GAAAAGGAAACAGGAAACCCAGTA probes 1 FAM-CAACCCTTCCGATAGG-MGB probes 2 VIC-TTCAACCCTCCCGATAG-MGB rs2933249 forward sequence GGCTAAGGCTGTAGGGATTGG reverse sequence TCCCAGATGTCCTTTGAATAATCA probes 1 FAM-TGCTTCTCCTTCTTCAGT-MGB probes 2 VIC-TGCTTCTCCTTCCTC-MGB rs275646 forward sequence GGAAATTCATCTTTTTGGACATCA reverse sequence CAACAAGAGTGAAACTCCATCTCAA probes 1 FAM-ATCATTTTTCAAGTATGGTGAG-MGB probes 2 VIC-CATCATTTTTCAAGTACGG-MGB Linear regression was applied to analyze the association between the gene polymorphisms and HTG risk. The association between the tag-SNPs and HTG risk was analyzed using SNPAssoc package of R. The potential gene-gene interactions among the selected polymorphisms were validated using model-based multifactor dimensionality reduction (MB-MDR) method[20]. All the statistical analyses were performed using R (X64 3.2.5) and SAS 9.4. P ≤ 0.05 was considered to be statistically significant.
In this study, among the 1, 591 participants 29.4% were identified as HTG patients and 44.4% of these HTG patients were males. The HTG group exhibited a higher systolic BP (SBP) and diastolic BP (DBP), body mass index (BMI), WC, TG, total cholesterol (TC), low-density lipoprotein cholesterol LDL-C, and fast blood glucose (FBG) levels as well as propensity for smoking and drinking than those in the normal-TG group. Contradictorily, the high-density lipoprotein cholesterol (HDL-C) levels in the HTG group were lower than those in the normal-TG group (Table 1).
Table 1. Baseline Characteristics of the Participants in This Study
Variables Group HTG (n = 482) Normal-TG (n = 1, 109) t/χ2 P Gender Male 214 (44.4) 468 (42.2) 0.66 0.421 Female 268 (55.6) 641 (57.8) Age (year) 56.10 ± 9.95 53.90 ± 9.59 0.38 0.886 Blood pressure (mmHg) SBP 127.51 ± 16.32 123.81 ± 16.41 4.13 < 0.001 DBP 80.72 ± 11.76 78.42 ± 11.20 3.71 < 0.001 TC (mmol/L) 5.23 ± 1.03 4.70 ± 0.82 9.95 < 0.001 TG (mmol/L) 2.97 ± 1.40 1.03 ± 0.34 29.92 < 0.001 HDL-C (mmol/L) 1.31 ± 0.33 1.43 ± 0.28 6.53 < 0.001 LDL-C (mmol/L) 2.74 ± 0.85 2.58 ± 0.61 3.70 < 0.001 FBG (mmol/L) 5.81 ± 1.04 5.57 ± 0.79 4.47 < 0.001 BMI (kg/m2) 24.63 ± 2.87 23.07 ± 2.95 9.78 < 0.001 WC (cm) 83.16 ± 8.06 79.32 ± 8.11 6.76 < 0.001 Smoking Yes 156 (32.4) 300 (27.1) 4.64 0.032 No 326 (67.6) 809 (72.9) Drinking Yes 100 (20.7) 183 (16.5) 4.14 0.041 No 382 (79.3) 926 (83.5) After adjustment based on the gender, age, BMI, and drinking and smoking propensity, the homozygous wild type A allele (AA, recessive model) of rs13433696 was associated with a decreased HTG risk compared to the carriers of (GA+AA) genotype (difference =-0.186, 95% CI =-0.362 to-0.011, P = 0.038). However, the homozygous wild type C allele (CC, recessive model) of rs5182 was associated with an increased HTG risk compared to the carriers of (TT+TC) genotype (difference = 0.208, 95% CI = 0.001 -0.415, P = 0.049) (Table 2). However, the remaining ten SNPs did not exhibit any association with HTG after the covariates adjustment (Supplementary Tables S3-S4, available in www.besjournal.com). The results of Hardy-Weinberg equilibrium (HWE) test to identify candidate SNPs was presented in Supplementary Table S5 (available in www.besjournal.com).
Table 2. Association of the Selected SNP Genotypes with HTG
SNP Model Genotype n(%) Me Se dif 95% CI P AIC rs13433696 Codominant G/G 658 (41.6) 1.639 0.048 0.000 1 0.112 5, 099 G/A 714 (45.1) 1.650 0.047 0.016 -0.112, 0.145 A/A 210 (13.3) 1.461 0.067 -0.178 -0.366, 0.010 Dominant G/G 658 (41.6) 1.639 0.048 0.000 1 0.652 5, 101 G/A-A/A 924 (58.4) 1.607 0.040 -0.028 -0.149, 0.093 Recessive G/G-G/A 1, 372 (86.7) 1.645 0.034 0.000 1 0.038 5, 097 A/A 210 (13.3) 1.461 0.067 -0.186 -0.362, -0.011 Overdominant G/G-A/A 868 (54.9) 1.596 0.040 0.000 1 0.332 5, 100 G/A 714 (45.1) 1.650 0.047 0.059 -0.061, 0.179 rs5182 Codominant T/T 754 (47.4) 1.638 0.045 0.000 1 0.069 5, 121 T/C 692 (43.5) 1.563 0.044 -0.077 -0.202, 0.048 C/C 144 (9.1) 1.811 0.108 0.171 -0.044, 0.387 Dominant T/T 754 (47.4) 1.638 0.045 0.000 1 0.577 5, 124 T/C-C/C 836 (52.6) 1.606 0.041 -0.034 -0.153, 0.085 Recessive T/T-T/C 1, 446 (91.9) 1.602 0.032 0.000 1 0.049 5, 120 C/C 144 (9.1) 1.811 0.108 0.208 0.001, 0.415 Overdominant T/T-C/C 898 (76.7) 1.666 0.042 0.000 1 0.657 5, 124 T/C 692 (43.5) 1.563 0.044 -0.105 -0.225, 0.016 Note. Adjusted for age, sex, BMI, drinking and smoking propensities. Dif, difference. AIC, Akake information criterion. Table Supplementary Table S3. Associations of the Selected SNPs Genotypes in PPARγ Gene with HTG
SNP Model Genotype n(%) me se dif Lower, upper P AIC rs12631819 Codominant G/G 623 (39.3) 1.674 0.052 0.000 1 0.186 5104 G/T 759 (47.9) 1.609 0.042 -0.006 -0.193, 0.064 T/T 202 (12.8) 1.505 0.070 -0.176 -0.368, 0.016 Dominant G/G 623 (39.3) 1.674 0.000 0.000 1 0.156 5103 G/T-T/T 961 (60.7) 1.587 0.037 -0.088 -0.211, 0.034 Recessive G/G-G/T 1, 382 (87.2) 1.638 0.033 0.000 1 0.123 5103 T/T 202 (12.8) 1.505 0.070 -0.141 -0.320, -0.038 Overdominant G/G-T/T 825 (52.1) 1.632 0.043 0.000 1 0.719 5105 G/T 759 (47.9) 1.609 0.043 -0.022 -0.142, 0.098 rs12920502 Codominant G/G 817 (51.6) 1.603 0.040 0.000 1 0.713 5106 G/C 659 (41.6) 1.632 0.048 0.032 -0.093, 0.156 C/C 107 (6.8) 1.701 0.149 0.094 -0.150, 0.338 Dominant G/G 817 (51.6) 1.603 0.040 0.000 1 0.509 5104 G/C-C/C 766 (48.4) 1.642 0.046 0.040 -0.079, 0.160 Recessive G/G-G/C 1, 476 (83.2) 1.616 0.031 0.000 1 0.511 5104 C/C 107 (6.8) 1.701 0.149 0.080 -0.158, 0.317 Overdominant G/G-T/T 924 (58.4) 1.614 0.039 0.000 1 0.738 5105 G/T 659 (41.6) 1.609 0.048 0.021 -0.100, 0.142 rs3656806 Codominant C/C 882 (55.9) 1.654 0.042 0.000 1 0.391 5066 C/T 588 (37.3) 1.583 0.048 -0.066 -0.192, 0.059 T/T 107 (6.8) 1.515 0.093 -0.135 -0.377, 0.106 Dominant C/C 882 (55.9) 1.615 0.034 0.000 1 0.689 5126 C/T-T/T 695 (44.1) 1.573 0.043 -0.077 -0.197, 0.043 Recessive C/C-C/T 1, 470 (93.2) 1.625 0.032 0.000 1 0.367 5065 T/T 107 (6.8) 1.515 0.093 -0.109 -0.345, 0.127 Overdominant C/C-T/T 989 (62.7) 1.639 0.039 0.000 1 0.411 5065 C/T 588 (37.3) 1.583 0.048 -0.052 -0.174, 0.071 rs1175543 Codominant A/A 479 (30.2) 1.606 0.057 0.000 1 0.551 5114 A/G 800 (50.4) 1.601 0.038 0.003 -0.134, 0.140 G/G 307 (19.4) 1.696 0.083 0.086 -0.088, 0.259 Dominant A/A 479 (30.2) 1.606 0.057 0.000 1 0.692 5113 A/G-G/G 1, 107 (69.8) 1.627 0.036 0.026 -0.104, 0.156 Recessive A/A-A/G 1, 279 (80.6) 1.603 0.032 0.000 1 0.275 5112 G/G 307 (19.4) 1.696 0.083 0.084 -0.067, 0.235 Overdominant A/A-G/G 786 (49.6) 1.641 0.047 0.000 1 0.618 5113 A/G 800 (50.4) 1.601 0.038 -0.030 -0.150, 0.089 rs9817428 Codominant A/A 477 (30.1) 1.617 0.059 0.000 1 0.259 5116 A/C 786 (49.5) 1.585 0.038 0.003 -0.162, 0.114 C/C 324 (20.4) 1.720 0.078 0.086 -0.064, 0.277 Dominant A/A 477 (30.1) 1.617 0.059 0.000 1 0.829 5117 A/C-C/C 1, 110 (69.9) 1.625 0.035 0.014 -0.116, 0.144 Recessive A/A-A/C 1, 263 (79.6) 1.597 0.033 0.000 1 0.108 5114 C/C 324 (20.4) 1.720 0.077 0.121 -0.026, 0.269 Overdominant A/A-C/C 801 (49.6) 1.659 0.047 0.000 1 0.271 5116 A/C 786 (50.4) 1.585 0.038 -0.067 -0.186, 0.052 rs2972164 Codominant C/C 1, 344 (84.5) 1.625 0.033 0.000 1 0.778 5126 C/T 237 (14.9) 1.610 0.081 -0.017 -0.185, 0.150 T/T 9 (0.6) 1.324 0.156 -0.277 -1.071, 0.516 Dominant C/C 1, 344 (84.5) 1.625 0.033 0.000 1 0.749 5124 C/T-T/T 246 (15.5) 1.600 0.078 -0.027 -0.191, 0.138 Recessive C/C-C/T 1, 581 (99.4) 1.623 0.031 0.000 1 0.497 5124 T/T 9 (0.6) 1.324 0.156 -0.275 -1.068, 0.518 Overdominant C/C-T/T 1, 353 (85.1) 1.623 0.033 0.000 1 0.856 5124 C/T 237 (14.9) 1.610 0.081 -0.016 -0.183, 0.152 Note. Adjusted for age, sex, BMI, drinking and smoking. Table Supplementary Table S4. Associations of the Selected SNPs Genotypes in AGTR1 Gene with HTG
SNP Model Genotype n(%) me se dif Lower, upper P AIC rs2638360 Codominant T/T 1, 294 (81.3) 1.615 0.034 0.000 1 0.544 5127 T/C 286 (18.0) 1.633 0.068 0.017 -0.138, 0.172 C/C 11 (0.7) 2.011 0.326 0.399 -0.319, 1.117 Dominant T/T 1, 294 (81.9) 1.615 0.034 0.000 1 0.689 5126 T/C-C/C 297 (18.7) 1.647 0.067 -0.031 -0.121, 0.184 Recessive T/T-T/C 1, 580 (99.3) 1.618 0.030 0.000 1 0.279 5125 C/C 11 (0.7) 2.011 0.326 0.396 -0.321, 1.113 Overdominant T/T-C/C 1, 305 (82.0) 1.618 0.034 0.000 1 0.863 5127 T/C 286 (18.0) 1.633 0.068 0.014 -0.141, 0.168 rs1492100 Codominant A/A 1, 200 (76.1) 1.651 0.035 0.000 1 0.148 5088 A/T 347 (22.0) 1.515 0.063 -0.133 -0.278, 0.012 T/T 30 (1.9) 1.781 0.234 0.140 -0.299, 0.579 Dominant A/A 1, 200 (76.1) 1.651 0.035 0.000 1 0.120 5088 A/T-T/T 377 (23.9) 1.536 0.061 -0.111 -0.252, 0.029 Recessive A/A-A/T 1, 547 (90.1) 1.620 0.031 0.000 1 0.448 5090 T/T 30 (1.9) 1.781 0.233 0.170 -0.269, 0.608 Overdominant A/A-T/T 1, 230 (88.0) 1.654 0.035 0.000 1 0.064 5087 A/T 347 (22.0) 1.515 0.063 -0.137 -0.281, 0.008 rs293249 Codominant C/C 1, 198 (75.6) 1.608 0.035 0.000 1 0.458 5108 C/T 356 (22.5) 1.651 0.065 0.044 -0.100, 0.187 T/T 30 (1.9) 1.851 0.212 0.255 -0.184, 0.694 Dominant C/C 1, 198 (75.6) 1.608 0.035 0.000 1 0.397 5106 C/T-T/T 386 (24.4) 1.666 0.624 -0.060 -0.079, 0.199 Recessive C/C-C/T 1, 554 (98.1) 1.618 0.031 0.000 1 0.272 5106 T/T 30 (1.9) 1.851 0.212 0.245 -0.192, 0.683 Overdominant C/C-T/T 1, 228 (77.5) 1.614 0.034 0.000 1 0.608 5107 C/T 356 (22.5) 1.651 0.065 0.037 -0.105, 0.180 rs275646 Codominant C/C 1, 212 (76.8) 1.619 0.034 0.000 1 0.290 5071 C/T 344 (21.8) 1.647 0.069 0.032 -0.112, 0.176 T/T 23 (1.4) 1.267 0.150 -0.376 -0.872, 0.121 Dominant C/C 1, 212 (76.8) 1.619 0.034 0.000 1 0.930 5071 C/T-T/T 367 (23.2) 1.623 0.066 0.006 -0.134, 0.147 Recessive C/C-C/T 1, 556 (98.6) 1.625 0.031 0.000 1 0.131 5069 T/T 23 (1.4) 1.267 0.150 -0.382 -0.878, 0.113 Overdominant C/C-T/T 1, 235 (78.2) 1.613 0.034 0.000 1 0.597 5071 C/T 344 (21.8) 1.647 0.069 0.039 -0.105, 0.183 Note. Adjusted for age, sex, BMI, drinking and smoking. Table Supplementary Table S5. HWE Test for Candidate SNPs of PPARG Gene and AGTR1 Gene for Both HTG and Normal-TG Group
Gene SNP WT/HT/MT HTG P Normal-TG P PPARG rs12631819 GG/GT/TT 191/233/56 0.235 432/526/146 0.476 rs2920502 GG/GC/CC 246/200/33 0.371 541/459/74 0.154 rs3856806 CC/CT/TT 271/174/33 0.572 611/414/75 0.669 rs13433696 GG/GA/AA 205/220/53 0.599 493/494/157 0.235 rs1175543 AA/AG/GG 141/246/92 0.406 338/554/215 0.655 rs9817428 AA/AC/CC 210/225/103 0.100 267/531/221 0.157 rs2972164 CC/CT/TT 416/64/2 0.782 928/173/7 0.729 AGTR1 rs2638360 TT/TC/CC 384/92/6 0.854 910/194/5 0.115 rs1492100 AA/AT/TT 330/136/12 0.648 870/211/18 0.213 rs5182 TT/TC/CC 221/205/56 0.423 533/487/88 0.109 rs2933249 CC/CT/TT 353/111/15 0.092 845/245/15 0.560 rs275646 CC/CT/TT 364/109/6 0.497 848/235/17 0.876 Note. WT wild type, HT heterozygote, MT mutant type. We observed that 2 to 9-locus models were significantly associated with HTG by quantitative trait that indicated a potential gene-gene interaction among rs5182, rs1492100, rs2972164, rs9817428, rs1175543, rs3856806, rs2920502, rs2638360, and rs12631819 after adjustment for gender, age, drinking and smoking status (Table 3). As rs13433696 in PPARγ as well as rs5182 in AGTR1 were potentially associated with HTG risk, we further analyzed the gene-gene interactions among the remaining ten SNPs using MB-MDR method (Supplementary Table S6, available in www.besjournal.com).
Table 3. Best Gene-gene Interaction Models Identified Using Model-based Multifactor Dimensionality Reduction Method
Locus No. Best Model NHa βHb WHc NLd WLe βLf Wmaxg Riskh Permi 2 rs9817428, rs1175543 1 3.76 19.54 0 NA NA 19.54 H 0.003 3 rs9817428, rs13433696, rs2638360 2 2.81 27.38 1 3.57 -0.19 27.38 H 0.015 4 rs2972164, rs13433696, rs6817428, rs2638360 3 4.39 54.37 2 5.41 -0.23 54.37 H 0.004 5 rs5182, rs1175543, rs13433696, rs3856806, rs2920502 14 1.18 85.75 3 8.93 -0.51 85.75 H 0.014 6 rs2972164, rs5182, rs9817428, rs1175543, rs3856806, rs2920502 17 1.87 144.20 3 12.22 -0.57 144.20 H 0.012 7 rs2972164, rs5182, rs9817428, rs1175543, rs3856806, rs2920502, rs2638360 25 2.27 216.70 2 6.43 6.43 216.70 H 0.004 8 rs275646, rs5182, rs9817428, rs1175543, rs13433696, rs3856806, rs2920502, rs2638360 32 2.31 262.00 1 3.41 -0.67 262.00 H 0.037 9 rs5182, rs1492100, rs2972164, rs9817428, rs1175543, rs3856806, rs2920502, rs2638360, rs12631819 33 2.58 291.60 1 4.11 -0.74 291.60 H 0.030 10 rs275646, rs5182, rs1492100, rs9817428, rs1175543, rs13433696, rs3856806, rs2920502, rs2638360, rs12631819 47 2.13 342.40 2 6.59 -0.77 342.40 H 0.139 Note. aThe merged number of cells of high-risk categories. bThe regression coefficient of high-risk categories. cThe Wald test value of high-risk categories. dThe merged number of cells of low-risk categories. eThe regression coefficient of low-risk categories. fThe Wald test value of low-risk categories. gWmax = max(WH, WL). hThe categories of combinatorial model tested using Perm. P (H: high-risk; L: low-risk). iAdjusted for age, sex, BMI, TC, TG, HDL-C, LDL-C, FBG, smoking, and drinking with 1, 000 times replacement. Table Supplementary Table S6. Best Gene-gene Interaction Models Identified by the Model-based Multifactor Dimensionality Reduction Method
Locus No. Best model NHa betaHb WHc NLd WLe betaLf Wmaxg Riskh Permi 2 rs9817428, rs1175543 1 3.76 19.54 0 NA NA 19.54 H 0.004 3 rs9817428, rs1175543, rs2638360 2 3.50 25.44 0 NA NA 25.44 H 0.013 4 rs9817428, rs1175543, rs2920502, rs2638360 3 3.80 51.31 2 10.86 -0.33 51.31 H 0.005 5 rs2933249, rs9817428, rs1175543 rs3856806, rs2920502 10 1.36 71.60 3 8.26 -0.34 71.60 H 0.018 6 rs275646, rs9817428, rs1175543, rs2638360, rs3856806, rs2920502 16 1.65 116.10 2 6.90 -0.43 116.10 H 0.010 7 rs275646, rs9817428, rs1175543, rs2638360, rs3856806, rs2920502, rs12631819 20 2.02 140.60 2 6.66 -0.45 140.60 H 0.038 8 rs275646, rs2933249, rs1492100, rs2972164, rs1175543, rs3856806, rs2920502, rs2638360 25 1.59 147.30 1 2.72 -0.70 147.30 H 0.165 Note. aThe merged number of cells of high-risk categories. bThe regression coefficient of high-risk categories. cThe Wald test value of high-risk categories. dThe merged number of cells of low-risk categories. eThe regression coefficient of low-risk categories. fThe Wald test value of low-risk categories. gWmax = max (WH, WL). hThe categories of combinatorial model tested by Perm. P (H: high-risk; L: low-risk). iAdjusted for age, sex, BMI, TC, TG, HDL-C, LDL-C, FBG, smoking, and drinking with 1, 000 times replacement. In the present study, our results demonstrated that the AA genotype individuals with rs13433696 in PPARγ exhibited a decreased HTG risk, while the CC genotype individuals with rs5182 in ATGR1 exhibited an increased HTG risk. Furthermore, we observed that the gene-gene interactions existed in the HTG-associated SNPs as well as HTG-non-associated SNPs of PPARγ and AGTR1.
Although the studies that analyzed the association between AGTR1 polymorphisms and risk of HTG are rare, the association between rs5182 SNP and BP was extensively discussed[4-6]. Additionally, in a case-control study, screening the exon 5 and 3x-untranslated region of ATGR1 demonstrated that solely the +1166 SNP in the 3x-untranslated region was significantly associated with hypertension among the five polymorphisms that are +573 (rs5182), +1062, +1166, +1517, and +1878. Therefore, although our results from the present study suggest that rs5182 in C allele is a risk factor for HTG, further studies are necessary to investigate the functions of ATGR1 polymorphisms.
Our previous studies suggested that PPARγ polymorphisms such as rs3856806 allele are significantly associated with the apoA-I/apoB ratio in the Chinese Han population[7]. Additionally, Chan et al. found a borderline significant association between the Pro12Ala (rs1801282) variant in PPARγ and risk of T2DM in women's health initiative-observational study (WHI-OS)[8]. Moreover, the results of a study in Kazakh population suggested that PPARγ polymorphism rs1175543 is significantly associated with metabolic syndromes[9]. In this study, we reported that a novel variant of AA genotype with rs13433696 in PPARγ is significantly associated with HTG susceptibility indicating that the polymorphisms of PPARγ might play a critical role in dyslipidemia associated diseases.
PPARγ inactivation leads to familial partial lipodystrophy (FPLD) syndrome associated with early-onset severe hypertension[10]. Considering that PPARγ and AGTR1 are located on the chromosome 3, it is not surprising that the gene-gene interactions exist not only in HTG-associated SNPs but also in HTG-non-associated SNPs.
In conclusion, the present study suggested that the polymorphisms of PPARγ and AGTRI contribute to the HTG risk either independently or in an interactive manner in the Chinese population. Further multiple comprehensive studies must be performed to confirm this genetic association using large sample size and to analyze the probable interactions of these SNPs with other gene variants.
doi: 10.3967/bes2018.084
Association of PPARγ and AGTR1 Polymorphisms with Hypertriglyceridemia in Chinese Population
-
-
Supplementary Table S1. Biological Information about Candidate SNPs of PPARG Gene and AGTR1 Gene
Gene tagSNPs HGVS Nomenclature Chromosome Allelesa Region Biological Effect Transcription Factor Binding Site MAFb, c PPARG rs12631819 NC_000003.12: g.12301362G > T 3 G/T 12301362 intron variant cap 0.378/0.402 rs2920502 NC_000003.12: g.12287696G > C 3 G/C 12287696 upstream variant 2KB cap 0.273/0.244 rs3856806 NC_000003.12: g.12434058C > 3 C/T 12434058 intron variant, synonymous codon, utr variant 3 prime - 0.268/0.250 rs13433696 NC_000003.12: g.12316993G > A 3 G/A 12316993 intron variant Skn-1, cap 0.378/0.390 rs1175543 NC_000003.12: g.12424934A > G 3 A/G 12424934 intron variant CdxA 0.450/0.484 rs9817428 NC_000003.12: g.12298768C > A 3 A/C 12298768 intron variant HSF, SRY 0.435/0.402 rs2972164 NC_000003.12: g.12292917T > C 3 C/T 12292917 intron variant CdxA, Abd-B 0.090/0.073 AGTR1 rs2638360 NC_000003.12: g.148710569G > A 3 T/C 148710569 intron variant CdxA, Dfd, Oct-1, Skn-1, cap, STATx, C/EBPa 0.077/0.156 rs1492100 NC_000003.12: g.148719640T > A 3 A/T 148719640 intron variant Hb 0.122/0.098 rs5182 NC_000003.12: g.148741608C > T 3 T/C 148741608 synonymous codon - 0.306/0.433 rs2933249 NC_000003.12: g.148698733G > A 3 C/T 148698733 intron variant HSF 0.128/0.098 rs275646 NC_000003.12: g.148745735T > C 3 C/T 148745735 - - 0.120/0.110 Note. aMajor/minor allele. bMAF in the control. cMAF in CHB. Supplementary Table S2. The Informations about the Primers and Probes of the Candidate SNPs of PPARG Gene and AGTR1 Gene
Gene SNP Primers and Probes PPARG rs12631819 forward sequence AAATGAGGCCAAAACTTGATAGTGT reverse sequence AAGGTTTACAATAATGCCCAGTACAA probes 1 FAM-AAGTTTAAGAAGAGAACCAG-MGB probes 2 HEX-AGTTTAAGAAGAGAACAAGT-MGB rs2920502 forward sequence GCACAGTAGGGCCCACG reverse sequence GGATCCCTCCTCGGAAATG probes 1 FAM-CCACTCTCTGCCC-MGB probes 2 HEX-CCACTGTCTGCCC-MGB rs3856806 forward sequence CGTCTTCTTGATCACCTGCAGTA reverse sequence AAAATGACAGACCTCAGACAGATTGT probes 1 FAM-CTGCACGTGTTCC-MGB probes 2 HEX-CTGCACATGTTCC-MGB rs13433696 forward sequence GAGGGAGAAAAGGGTTTAGATAAAAGA reverse sequence TGCTCCATCCAGTACATCTATAATTGA probes 1 FAM-AACTTGTTTGGTCTCAGTG-MGB probes 2 VIC-ACTTGTTTGGTCTCAATGA-MGB rs1175543 forward sequence ATGTGAAGCCTCTGGCACAAT reverse sequence ATATAGGGCAAAAGGGAAAATTAGC probes 1 FAM-TTCAGCACACAGTAAA-MGB probes 2 VIC-TTCAGCACACAATAA-MGB rs9817428 forward sequence AAAATAAAACGCATCAGTCTCAGTAGAT reverse sequence GCCAAGACAAACTTCAGCTAACAA probes 1 FAM-ATCATCACATCGAGTTT-MGB probes 2 VIC-TATCATCACATCGAGGTT-MGB rs2972164 forward sequence CTGGACTGGCAAGCCACTCT reverse sequence GCATCCTTTTAGTGAAGTCCCTACTT probes 1 FAM-AGTGTGGAGCTATAAA-MGB probes 2 VIC-AGTGTGGAGCTACAAA-MGB AGTR1 rs2638360 forward sequence GCCAATATTTTCTTCCTTACTCATTACC reverse sequence GTTTGGCTCTCCAACTGCTTAAA probes 1 FAM-TTTCTTTAGTTTTCCAGTAAT-MGB probes 2 HEX-TCTTTAGTTTTCCAATAAT-MGB rs1492100 forward sequence CCTGTGCTGTTCTCAGGTTCTG reverse sequence CACATGGAGTTTCCCTCTCATG probes 1 FAM-ATTGGATGGCTTTTT-MGB probes 2 VIC-ATTGGATGGCTATTTAG-MGB rs5182 forward sequence TGCTTTCCATTATGAGTCCCAAA reverse sequence GAAAAGGAAACAGGAAACCCAGTA probes 1 FAM-CAACCCTTCCGATAGG-MGB probes 2 VIC-TTCAACCCTCCCGATAG-MGB rs2933249 forward sequence GGCTAAGGCTGTAGGGATTGG reverse sequence TCCCAGATGTCCTTTGAATAATCA probes 1 FAM-TGCTTCTCCTTCTTCAGT-MGB probes 2 VIC-TGCTTCTCCTTCCTC-MGB rs275646 forward sequence GGAAATTCATCTTTTTGGACATCA reverse sequence CAACAAGAGTGAAACTCCATCTCAA probes 1 FAM-ATCATTTTTCAAGTATGGTGAG-MGB probes 2 VIC-CATCATTTTTCAAGTACGG-MGB Table 1. Baseline Characteristics of the Participants in This Study
Variables Group HTG (n = 482) Normal-TG (n = 1, 109) t/χ2 P Gender Male 214 (44.4) 468 (42.2) 0.66 0.421 Female 268 (55.6) 641 (57.8) Age (year) 56.10 ± 9.95 53.90 ± 9.59 0.38 0.886 Blood pressure (mmHg) SBP 127.51 ± 16.32 123.81 ± 16.41 4.13 < 0.001 DBP 80.72 ± 11.76 78.42 ± 11.20 3.71 < 0.001 TC (mmol/L) 5.23 ± 1.03 4.70 ± 0.82 9.95 < 0.001 TG (mmol/L) 2.97 ± 1.40 1.03 ± 0.34 29.92 < 0.001 HDL-C (mmol/L) 1.31 ± 0.33 1.43 ± 0.28 6.53 < 0.001 LDL-C (mmol/L) 2.74 ± 0.85 2.58 ± 0.61 3.70 < 0.001 FBG (mmol/L) 5.81 ± 1.04 5.57 ± 0.79 4.47 < 0.001 BMI (kg/m2) 24.63 ± 2.87 23.07 ± 2.95 9.78 < 0.001 WC (cm) 83.16 ± 8.06 79.32 ± 8.11 6.76 < 0.001 Smoking Yes 156 (32.4) 300 (27.1) 4.64 0.032 No 326 (67.6) 809 (72.9) Drinking Yes 100 (20.7) 183 (16.5) 4.14 0.041 No 382 (79.3) 926 (83.5) Table 2. Association of the Selected SNP Genotypes with HTG
SNP Model Genotype n(%) Me Se dif 95% CI P AIC rs13433696 Codominant G/G 658 (41.6) 1.639 0.048 0.000 1 0.112 5, 099 G/A 714 (45.1) 1.650 0.047 0.016 -0.112, 0.145 A/A 210 (13.3) 1.461 0.067 -0.178 -0.366, 0.010 Dominant G/G 658 (41.6) 1.639 0.048 0.000 1 0.652 5, 101 G/A-A/A 924 (58.4) 1.607 0.040 -0.028 -0.149, 0.093 Recessive G/G-G/A 1, 372 (86.7) 1.645 0.034 0.000 1 0.038 5, 097 A/A 210 (13.3) 1.461 0.067 -0.186 -0.362, -0.011 Overdominant G/G-A/A 868 (54.9) 1.596 0.040 0.000 1 0.332 5, 100 G/A 714 (45.1) 1.650 0.047 0.059 -0.061, 0.179 rs5182 Codominant T/T 754 (47.4) 1.638 0.045 0.000 1 0.069 5, 121 T/C 692 (43.5) 1.563 0.044 -0.077 -0.202, 0.048 C/C 144 (9.1) 1.811 0.108 0.171 -0.044, 0.387 Dominant T/T 754 (47.4) 1.638 0.045 0.000 1 0.577 5, 124 T/C-C/C 836 (52.6) 1.606 0.041 -0.034 -0.153, 0.085 Recessive T/T-T/C 1, 446 (91.9) 1.602 0.032 0.000 1 0.049 5, 120 C/C 144 (9.1) 1.811 0.108 0.208 0.001, 0.415 Overdominant T/T-C/C 898 (76.7) 1.666 0.042 0.000 1 0.657 5, 124 T/C 692 (43.5) 1.563 0.044 -0.105 -0.225, 0.016 Note. Adjusted for age, sex, BMI, drinking and smoking propensities. Dif, difference. AIC, Akake information criterion. Supplementary Table S3. Associations of the Selected SNPs Genotypes in PPARγ Gene with HTG
SNP Model Genotype n(%) me se dif Lower, upper P AIC rs12631819 Codominant G/G 623 (39.3) 1.674 0.052 0.000 1 0.186 5104 G/T 759 (47.9) 1.609 0.042 -0.006 -0.193, 0.064 T/T 202 (12.8) 1.505 0.070 -0.176 -0.368, 0.016 Dominant G/G 623 (39.3) 1.674 0.000 0.000 1 0.156 5103 G/T-T/T 961 (60.7) 1.587 0.037 -0.088 -0.211, 0.034 Recessive G/G-G/T 1, 382 (87.2) 1.638 0.033 0.000 1 0.123 5103 T/T 202 (12.8) 1.505 0.070 -0.141 -0.320, -0.038 Overdominant G/G-T/T 825 (52.1) 1.632 0.043 0.000 1 0.719 5105 G/T 759 (47.9) 1.609 0.043 -0.022 -0.142, 0.098 rs12920502 Codominant G/G 817 (51.6) 1.603 0.040 0.000 1 0.713 5106 G/C 659 (41.6) 1.632 0.048 0.032 -0.093, 0.156 C/C 107 (6.8) 1.701 0.149 0.094 -0.150, 0.338 Dominant G/G 817 (51.6) 1.603 0.040 0.000 1 0.509 5104 G/C-C/C 766 (48.4) 1.642 0.046 0.040 -0.079, 0.160 Recessive G/G-G/C 1, 476 (83.2) 1.616 0.031 0.000 1 0.511 5104 C/C 107 (6.8) 1.701 0.149 0.080 -0.158, 0.317 Overdominant G/G-T/T 924 (58.4) 1.614 0.039 0.000 1 0.738 5105 G/T 659 (41.6) 1.609 0.048 0.021 -0.100, 0.142 rs3656806 Codominant C/C 882 (55.9) 1.654 0.042 0.000 1 0.391 5066 C/T 588 (37.3) 1.583 0.048 -0.066 -0.192, 0.059 T/T 107 (6.8) 1.515 0.093 -0.135 -0.377, 0.106 Dominant C/C 882 (55.9) 1.615 0.034 0.000 1 0.689 5126 C/T-T/T 695 (44.1) 1.573 0.043 -0.077 -0.197, 0.043 Recessive C/C-C/T 1, 470 (93.2) 1.625 0.032 0.000 1 0.367 5065 T/T 107 (6.8) 1.515 0.093 -0.109 -0.345, 0.127 Overdominant C/C-T/T 989 (62.7) 1.639 0.039 0.000 1 0.411 5065 C/T 588 (37.3) 1.583 0.048 -0.052 -0.174, 0.071 rs1175543 Codominant A/A 479 (30.2) 1.606 0.057 0.000 1 0.551 5114 A/G 800 (50.4) 1.601 0.038 0.003 -0.134, 0.140 G/G 307 (19.4) 1.696 0.083 0.086 -0.088, 0.259 Dominant A/A 479 (30.2) 1.606 0.057 0.000 1 0.692 5113 A/G-G/G 1, 107 (69.8) 1.627 0.036 0.026 -0.104, 0.156 Recessive A/A-A/G 1, 279 (80.6) 1.603 0.032 0.000 1 0.275 5112 G/G 307 (19.4) 1.696 0.083 0.084 -0.067, 0.235 Overdominant A/A-G/G 786 (49.6) 1.641 0.047 0.000 1 0.618 5113 A/G 800 (50.4) 1.601 0.038 -0.030 -0.150, 0.089 rs9817428 Codominant A/A 477 (30.1) 1.617 0.059 0.000 1 0.259 5116 A/C 786 (49.5) 1.585 0.038 0.003 -0.162, 0.114 C/C 324 (20.4) 1.720 0.078 0.086 -0.064, 0.277 Dominant A/A 477 (30.1) 1.617 0.059 0.000 1 0.829 5117 A/C-C/C 1, 110 (69.9) 1.625 0.035 0.014 -0.116, 0.144 Recessive A/A-A/C 1, 263 (79.6) 1.597 0.033 0.000 1 0.108 5114 C/C 324 (20.4) 1.720 0.077 0.121 -0.026, 0.269 Overdominant A/A-C/C 801 (49.6) 1.659 0.047 0.000 1 0.271 5116 A/C 786 (50.4) 1.585 0.038 -0.067 -0.186, 0.052 rs2972164 Codominant C/C 1, 344 (84.5) 1.625 0.033 0.000 1 0.778 5126 C/T 237 (14.9) 1.610 0.081 -0.017 -0.185, 0.150 T/T 9 (0.6) 1.324 0.156 -0.277 -1.071, 0.516 Dominant C/C 1, 344 (84.5) 1.625 0.033 0.000 1 0.749 5124 C/T-T/T 246 (15.5) 1.600 0.078 -0.027 -0.191, 0.138 Recessive C/C-C/T 1, 581 (99.4) 1.623 0.031 0.000 1 0.497 5124 T/T 9 (0.6) 1.324 0.156 -0.275 -1.068, 0.518 Overdominant C/C-T/T 1, 353 (85.1) 1.623 0.033 0.000 1 0.856 5124 C/T 237 (14.9) 1.610 0.081 -0.016 -0.183, 0.152 Note. Adjusted for age, sex, BMI, drinking and smoking. Supplementary Table S4. Associations of the Selected SNPs Genotypes in AGTR1 Gene with HTG
SNP Model Genotype n(%) me se dif Lower, upper P AIC rs2638360 Codominant T/T 1, 294 (81.3) 1.615 0.034 0.000 1 0.544 5127 T/C 286 (18.0) 1.633 0.068 0.017 -0.138, 0.172 C/C 11 (0.7) 2.011 0.326 0.399 -0.319, 1.117 Dominant T/T 1, 294 (81.9) 1.615 0.034 0.000 1 0.689 5126 T/C-C/C 297 (18.7) 1.647 0.067 -0.031 -0.121, 0.184 Recessive T/T-T/C 1, 580 (99.3) 1.618 0.030 0.000 1 0.279 5125 C/C 11 (0.7) 2.011 0.326 0.396 -0.321, 1.113 Overdominant T/T-C/C 1, 305 (82.0) 1.618 0.034 0.000 1 0.863 5127 T/C 286 (18.0) 1.633 0.068 0.014 -0.141, 0.168 rs1492100 Codominant A/A 1, 200 (76.1) 1.651 0.035 0.000 1 0.148 5088 A/T 347 (22.0) 1.515 0.063 -0.133 -0.278, 0.012 T/T 30 (1.9) 1.781 0.234 0.140 -0.299, 0.579 Dominant A/A 1, 200 (76.1) 1.651 0.035 0.000 1 0.120 5088 A/T-T/T 377 (23.9) 1.536 0.061 -0.111 -0.252, 0.029 Recessive A/A-A/T 1, 547 (90.1) 1.620 0.031 0.000 1 0.448 5090 T/T 30 (1.9) 1.781 0.233 0.170 -0.269, 0.608 Overdominant A/A-T/T 1, 230 (88.0) 1.654 0.035 0.000 1 0.064 5087 A/T 347 (22.0) 1.515 0.063 -0.137 -0.281, 0.008 rs293249 Codominant C/C 1, 198 (75.6) 1.608 0.035 0.000 1 0.458 5108 C/T 356 (22.5) 1.651 0.065 0.044 -0.100, 0.187 T/T 30 (1.9) 1.851 0.212 0.255 -0.184, 0.694 Dominant C/C 1, 198 (75.6) 1.608 0.035 0.000 1 0.397 5106 C/T-T/T 386 (24.4) 1.666 0.624 -0.060 -0.079, 0.199 Recessive C/C-C/T 1, 554 (98.1) 1.618 0.031 0.000 1 0.272 5106 T/T 30 (1.9) 1.851 0.212 0.245 -0.192, 0.683 Overdominant C/C-T/T 1, 228 (77.5) 1.614 0.034 0.000 1 0.608 5107 C/T 356 (22.5) 1.651 0.065 0.037 -0.105, 0.180 rs275646 Codominant C/C 1, 212 (76.8) 1.619 0.034 0.000 1 0.290 5071 C/T 344 (21.8) 1.647 0.069 0.032 -0.112, 0.176 T/T 23 (1.4) 1.267 0.150 -0.376 -0.872, 0.121 Dominant C/C 1, 212 (76.8) 1.619 0.034 0.000 1 0.930 5071 C/T-T/T 367 (23.2) 1.623 0.066 0.006 -0.134, 0.147 Recessive C/C-C/T 1, 556 (98.6) 1.625 0.031 0.000 1 0.131 5069 T/T 23 (1.4) 1.267 0.150 -0.382 -0.878, 0.113 Overdominant C/C-T/T 1, 235 (78.2) 1.613 0.034 0.000 1 0.597 5071 C/T 344 (21.8) 1.647 0.069 0.039 -0.105, 0.183 Note. Adjusted for age, sex, BMI, drinking and smoking. Supplementary Table S5. HWE Test for Candidate SNPs of PPARG Gene and AGTR1 Gene for Both HTG and Normal-TG Group
Gene SNP WT/HT/MT HTG P Normal-TG P PPARG rs12631819 GG/GT/TT 191/233/56 0.235 432/526/146 0.476 rs2920502 GG/GC/CC 246/200/33 0.371 541/459/74 0.154 rs3856806 CC/CT/TT 271/174/33 0.572 611/414/75 0.669 rs13433696 GG/GA/AA 205/220/53 0.599 493/494/157 0.235 rs1175543 AA/AG/GG 141/246/92 0.406 338/554/215 0.655 rs9817428 AA/AC/CC 210/225/103 0.100 267/531/221 0.157 rs2972164 CC/CT/TT 416/64/2 0.782 928/173/7 0.729 AGTR1 rs2638360 TT/TC/CC 384/92/6 0.854 910/194/5 0.115 rs1492100 AA/AT/TT 330/136/12 0.648 870/211/18 0.213 rs5182 TT/TC/CC 221/205/56 0.423 533/487/88 0.109 rs2933249 CC/CT/TT 353/111/15 0.092 845/245/15 0.560 rs275646 CC/CT/TT 364/109/6 0.497 848/235/17 0.876 Note. WT wild type, HT heterozygote, MT mutant type. Table 3. Best Gene-gene Interaction Models Identified Using Model-based Multifactor Dimensionality Reduction Method
Locus No. Best Model NHa βHb WHc NLd WLe βLf Wmaxg Riskh Permi 2 rs9817428, rs1175543 1 3.76 19.54 0 NA NA 19.54 H 0.003 3 rs9817428, rs13433696, rs2638360 2 2.81 27.38 1 3.57 -0.19 27.38 H 0.015 4 rs2972164, rs13433696, rs6817428, rs2638360 3 4.39 54.37 2 5.41 -0.23 54.37 H 0.004 5 rs5182, rs1175543, rs13433696, rs3856806, rs2920502 14 1.18 85.75 3 8.93 -0.51 85.75 H 0.014 6 rs2972164, rs5182, rs9817428, rs1175543, rs3856806, rs2920502 17 1.87 144.20 3 12.22 -0.57 144.20 H 0.012 7 rs2972164, rs5182, rs9817428, rs1175543, rs3856806, rs2920502, rs2638360 25 2.27 216.70 2 6.43 6.43 216.70 H 0.004 8 rs275646, rs5182, rs9817428, rs1175543, rs13433696, rs3856806, rs2920502, rs2638360 32 2.31 262.00 1 3.41 -0.67 262.00 H 0.037 9 rs5182, rs1492100, rs2972164, rs9817428, rs1175543, rs3856806, rs2920502, rs2638360, rs12631819 33 2.58 291.60 1 4.11 -0.74 291.60 H 0.030 10 rs275646, rs5182, rs1492100, rs9817428, rs1175543, rs13433696, rs3856806, rs2920502, rs2638360, rs12631819 47 2.13 342.40 2 6.59 -0.77 342.40 H 0.139 Note. aThe merged number of cells of high-risk categories. bThe regression coefficient of high-risk categories. cThe Wald test value of high-risk categories. dThe merged number of cells of low-risk categories. eThe regression coefficient of low-risk categories. fThe Wald test value of low-risk categories. gWmax = max(WH, WL). hThe categories of combinatorial model tested using Perm. P (H: high-risk; L: low-risk). iAdjusted for age, sex, BMI, TC, TG, HDL-C, LDL-C, FBG, smoking, and drinking with 1, 000 times replacement. Supplementary Table S6. Best Gene-gene Interaction Models Identified by the Model-based Multifactor Dimensionality Reduction Method
Locus No. Best model NHa betaHb WHc NLd WLe betaLf Wmaxg Riskh Permi 2 rs9817428, rs1175543 1 3.76 19.54 0 NA NA 19.54 H 0.004 3 rs9817428, rs1175543, rs2638360 2 3.50 25.44 0 NA NA 25.44 H 0.013 4 rs9817428, rs1175543, rs2920502, rs2638360 3 3.80 51.31 2 10.86 -0.33 51.31 H 0.005 5 rs2933249, rs9817428, rs1175543 rs3856806, rs2920502 10 1.36 71.60 3 8.26 -0.34 71.60 H 0.018 6 rs275646, rs9817428, rs1175543, rs2638360, rs3856806, rs2920502 16 1.65 116.10 2 6.90 -0.43 116.10 H 0.010 7 rs275646, rs9817428, rs1175543, rs2638360, rs3856806, rs2920502, rs12631819 20 2.02 140.60 2 6.66 -0.45 140.60 H 0.038 8 rs275646, rs2933249, rs1492100, rs2972164, rs1175543, rs3856806, rs2920502, rs2638360 25 1.59 147.30 1 2.72 -0.70 147.30 H 0.165 Note. aThe merged number of cells of high-risk categories. bThe regression coefficient of high-risk categories. cThe Wald test value of high-risk categories. dThe merged number of cells of low-risk categories. eThe regression coefficient of low-risk categories. fThe Wald test value of low-risk categories. gWmax = max (WH, WL). hThe categories of combinatorial model tested by Perm. P (H: high-risk; L: low-risk). iAdjusted for age, sex, BMI, TC, TG, HDL-C, LDL-C, FBG, smoking, and drinking with 1, 000 times replacement. -
[1] Abou Ziki MD, Mani A. Metabolic syndrome:genetic insights into disease pathogenesis. Curr Opin Lipidol, 2016; 27, 162-71. doi: 10.1097/MOL.0000000000000276 [2] Michel MC, Brunner HR, Foster C, et al. Angiotensin Ⅱ type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. Pharmacol Ther, 2016; 164, 1-81. doi: 10.1016/j.pharmthera.2016.03.019 [3] Qian X, Guo D, Zhou H, et al. Interactions between PPARG and AGTR1 gene polymorphisms on the risk of hypertension in Chinese han population. Genet Test Mol Biomarkers, 2018; 22, 90-7. doi: 10.1089/gtmb.2017.0141 [4] Martínezrodríguez N, Posadasromero C, Cardoso G, et al. Association of angiotensin Ⅱ type 1-receptor gene polymorphisms with the risk of developing hypertension in Mexican individuals. J Renin Angiotensin Aldosterone Syst, 2012; 13, 133-40. doi: 10.1177/1470320311419175 [5] Chaves FJ, Pascual JM, Rovira E, et al. Angiotensin Ⅱ AT1 receptor gene polymorphism and microalbuminuria in essential hypertension. Am J Hypertens, 2001; 14, 364-70. doi: 10.1016/S0895-7061(00)01284-X [6] Zhu X, Yan D, Cooper RS, et al. Linkage disequilibrium and haplotype diversity in the genes of the renin-angiotensin system:findings from the family blood pressure program. Genome Res, 2003; 13, 173-81. doi: 10.1101/gr.302003 [7] Hai B, Xie H, Guo Z, et al. Gene-Gene Interactions among Pparα/δ/γ Polymorphisms for Apolipoprotein (Apo) A-I/Apob Ratio in Chinese Han Population. Iran J Public Health, 2014; 43, 749-59. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Doaj000004067547 [8] Chan KH, Niu T, Ma Y, et al. Common genetic variants in peroxisome proliferator-activated receptor-γ (PPARG) and type 2 diabetes risk among Women's Health Initiative postmenopausal women. J Clin Endocrinol Metab, 2013; 98, E600-4. doi: 10.1210/jc.2012-3644 [9] Guo SX, Guo H, Ma RL, et al. Analysis of the haplotype and linkage disequilibrium of PPARγ gene polymorphisms rs3856806, rs12490265, rs1797912, and rs1175543 among patients with metabolic syndrome in Kazakh of Xinjiang Province. Genet Mol Res, 2014; 13, 8686-94. doi: 10.4238/2014.October.27.9 [10] Auclair M, Vigouroux C, Boccara F, et al. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system. Arterioscler Thromb Vasc Biol, 2013; 33, 829-38. doi: 10.1161/ATVBAHA.112.300962